



# **Spirometric Assessment before and after Treatment of Prostatic Hyperplasia in Patients with Chronic Obstructive Pulmonary Disease**

*Thesis*

*Submitted for Partial Fulfillment  
of Master Degree in Chest Diseases*

*By*

***Abdel Hamid Mohammed Shawky Hiekal***

*B.Ch, M.Sc*

*Under Supervision of*

**Prof. Aya Mohamed Mohamed Abdel Dayiem**

*Professor of Chest Diseases*

*Faculty of Medicine – Ain Shams University*

**Prof. Tarek Osman Elsayed**

*Professor of Urology*

*Faculty of Medicine – Ain Shams University*

**Assist. Prof. Hala Mohamed Salem**

*Assistant Professor of Chest Diseases*

*Faculty of Medicine – Ain Shams University*

***Faculty of Medicine  
Ain Shams University***

***2019***

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Aya Mohamed Mohamed Abdel Dayiem**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for her meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Tarek Osman Elsayed**, Professor of Urology, Faculty of Medicine, Ain Shams University, for his sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Assist. Prof. Hala Mohamed Salem**, Assistant Professor of Chest Diseases, Faculty of Medicine Ain Shams University, for her great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Abdel Hamid Mohammed Shawky Hiekal**

# List of Contents

Title	Page No.
List of Tables.....	5
List of Figures .....	7
Introduction .....	- 1 -
Aim of the Work .....	15
Review of Literature	
▪ Chronic Obstructive Pulmonary Disease .....	16
▪ Spirometry .....	31
▪ Benign Prostatic Hyperplasia .....	45
▪ Cholinergic Receptors Map in Airways and Prostates .....	71
Patients and Methods.....	78
Results.....	105
Discussion .....	125
Summary.....	132
Conclusion .....	135
Recommendations.....	136
References .....	137
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table (1):</b>	Factors influencing survival in patients with COPD.....	18
<b>Table (2):</b>	Spirometric classification of the severity of chronic obstructive pulmonary disease .....	23
<b>Table (3):</b>	Modified medical research council dyspnea scale.....	24
<b>Table (4):</b>	Lung volumes.....	35
<b>Table (5):</b>	Showing the demographic distribution of studied subjects and the degree of severity of obstruction .....	105
<b>Table (6):</b>	Showing the mean prostatic sizes between group A and group B, and mean mMRC between the two groups.....	109
<b>Table (7):</b>	Showing the relationship between grading of dyspnea by mMRC and patients' age in the two groups .....	110
<b>Table (8):</b>	Showing demographic distribution of the two groups according to the grading criteria of IPSS .....	111
<b>Table (9):</b>	Showing the relation between prostate size and age in the two groups: .....	112
<b>Table (10):</b>	Showing the mean values of spirometric assessment of patients in two groups in the first spirometry done before starting treatment for symptomatic benign prostatic hyperplasia.....	113
<b>Table (11):</b>	Showing the mean values of spirometric assessment of patients in two groups in the second spirometry done after starting treatment for symptomatic benign prostatic hyperplasia by one month .....	114

# List of Tables cont...

Table No.	Title	Page No.
<b>Table (12):</b>	Showing comparison between mean spirometric values between first spirometry (before starting treatment for symptomatic benign prostatic hyperplasia) and the second spirometry(done after one month of starting treatment) in group A patients(on tamsulosin only).....	115
<b>Table (13):</b>	Showing comparison between mean spirometric values between first spirometry (before starting treatment for symptomatic benign prostatic hyperplasia) and the second spirometry(done after one month of starting treatment) in group B patients(on tamsulosin and sofenacin).....	119
<b>Table (14):</b>	Showing comparison between the two groups in percent of change between values of spirometries done before and after treatment of symptomatic benign prostatic hyperplasia.....	123
<b>Table (15):</b>	Showing comparison between the two groups in absolute change between values of spirometries done before and after treatment of symptomatic benign prostatic hyperplasia .....	124

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	The refined ABCD assessment tool. ....	24
<b>Figure (2):</b>	Pharmacological treatment by GOLD grade.....	30
<b>Figure (3):</b>	Screen for spirometry readouts.....	33
<b>Figure (4):</b>	Lung volumes .....	34
<b>Figure (5):</b>	Normal Values for FVC, FEV1 and FEV 25-75%.....	38
<b>Figure (6):</b>	Normal values for peak expiratory flow (PEF). ....	44
<b>Figure (7):</b>	Obstructive disease by spirometry: Although all flow rates are diminished, expiratory prolongation predominates. ....	89
<b>Figure (8):</b>	Restrictive disease by spirometry: the flow-volume curve is narrowed because of diminished lung volumes, but the shape is generally the same as in normal volume.....	90
<b>Figure (9):</b>	Abdominal sonographic presentation of BPH. ....	96
<b>Figure (10):</b>	Showing digital rectal examination.....	96
<b>Figure (11):</b>	American urological association BPH symptom score index questionnaire. ....	98
<b>Figure (12):</b>	Showing demographic distribution in group A of studied subjects. ....	106
<b>Figure (13):</b>	Showing demographic distribution in group B of studied subjects. ....	107
<b>Figure (14):</b>	Showing spirometries' severity of obstruction in group A of studied subjects.....	107
<b>Figure (15):</b>	Showing spirometries' severity of obstruction in group B of studied subjects.....	108

# List of Figures cont...

Fig. No.	Title	Page No.
<b>Figure (16):</b>	Comparison between mean FVC before starting tamsulosin and mean FVC after starting tamsulosin by one month in group A of patients .....	116
<b>Figure (17):</b>	Comparison between mean FEV1 before starting tamsulosin and mean FEV1 after starting tamsulosin by one month in group A of patients. ....	117
<b>Figure (18):</b>	Comparison between mean percentage of FEV1 before starting tamsulosin and mean percentage of FEV1 after starting tamsulosin by one month in group A of patients. ....	118
<b>Figure (19):</b>	Comparison between mean FVC before starting tamsulosin and mean FVC after starting tamsulosin by one month in group B of patients. ....	120
<b>Figure (20):</b>	Comparison between mean FEV1 before starting tamsulosin and sofenacin and mean FEV1 after starting tamsulosin and sofenacin by one month in group B of patients. ....	121
<b>Figure (21):</b>	Comparison between mean percentage of FEV1 before starting tamsulosin and mean percentage of FEV1 after starting tamsulosin by one month in group B of patients. ....	122



# List of Abbreviations

Abb.	Full term
<i>5 AR</i> .....	<i>5 alpha reductase</i>
<i>Ach</i> .....	<i>Acetylchoine</i>
<i>AMP</i> .....	<i>Adenosine momophosphate</i>
<i>ATS</i> .....	<i>American Thoracic Society</i>
<i>AUA</i> .....	<i>American Urological association</i>
<i>AUR</i> .....	<i>Acute urinary retention</i>
<i>BD</i> .....	<i>Bladder detrusor</i>
<i>BII</i> .....	<i>BPH impact index</i>
<i>BOO</i> .....	<i>Bladder outlet obstruction</i>
<i>BPE</i> .....	<i>Benign prostatic enlargement</i>
<i>BPH</i> .....	<i>Benign prostatic hyperplasia</i>
<i>cAMP</i> .....	<i>Cyclic Adenosine momophosphate</i>
<i>CAT</i> .....	<i>COPD assessment test</i>
<i>COPD</i> .....	<i>Chronic obstructive pulmonary disease</i>
<i>CRP</i> .....	<i>C-reactive protien</i>
<i>CYP</i> .....	<i>Cytochrome p450</i>
<i>DHT</i> .....	<i>Dihydrotestosterone</i>
<i>DRE</i> .....	<i>Digital rectal examination</i>
<i>ERS</i> .....	<i>European Thoracic Society</i>
<i>ERV</i> .....	<i>Expiratory reserve volume</i>
<i>FEF max</i> .....	<i>Maximum instantaneous flow achieved</i>
<i>FEF</i> .....	<i>Forced expiratory flow</i>
<i>FEV1</i> .....	<i>Forced expiratory volume in first second</i>
<i>FIF</i> .....	<i>Forced inspiratory flow</i>
<i>FRC</i> .....	<i>Functional residual capacity</i>
<i>FVC</i> .....	<i>Forced vital capacity</i>
<i>GnRH</i> .....	<i>Gonadotropin releasing hormone</i>
<i>GOLD</i> .....	<i>Global initiative for chronic obstructive lung disease</i>

# List of Abbreviations cont...

Abb.	Full term
IC.....	<i>Inspiratory capacity</i>
ICS.....	<i>Inhaled corticosteroids</i>
IL .....	<i>Interleukin</i>
IPSS.....	<i>International prostate symptomes score</i>
IQR .....	<i>Interquartile range</i>
IRV.....	<i>Inspiratory reserve volume</i>
LABA .....	<i>Long acting beta-2 agonist</i>
LAMA .....	<i>Long acting antimuscarinics</i>
LUTS.....	<i>Lower urinary tract symptomes</i>
MMEF/MEF.....	<i>Maximal (mid-) expiratory flow</i>
mMRC .....	<i>Modified British Medical Research council</i>
MVV.....	<i>Maximal voluntary ventilation</i>
OAB .....	<i>Overactive bladder</i>
PaO2.....	<i>Partial Pressure of arterial Oxygen</i>
PCV13.....	<i>Pneumococcal conjugate vaclcine</i>
PEF.....	<i>Peak expiratory flow</i>
PFTs .....	<i>Pulmonary function tests</i>
PI .....	<i>Phosphate inositol</i>
PPSV23 .....	<i>Pneumococcalpolysaccharide vaclcine</i>
PSA.....	<i>Prostate surface antigen</i>
PVR.....	<i>Post void residual urine volume</i>
QoL .....	<i>Quality of life</i>
RCT .....	<i>Randomized controlled trial</i>
RV.....	<i>Residual volume</i>
SABA .....	<i>Short acting beta-2 agonist</i>
SAMA .....	<i>Short acting antimuscarinics</i>
SD.....	<i>Standard deviation</i>
SPI.....	<i>Symptomes problem Index</i>
SPSS.....	<i>Statistical package for social science</i>

# List of Abbreviations cont...

Abb.	Full term
<i>SRaW</i> .....	<i>Specific resistance if airway</i>
<i>TAUS</i> .....	<i>Transabdominal ultrasound</i>
<i>TLC</i> .....	<i>Total lung capacity</i>
<i>TRUS</i> .....	<i>Transrectal ultrasound</i>
<i>TUIP</i> .....	<i>Transurethral incision of the prostate</i>
<i>TUMT</i> .....	<i>Transurethral microwave thermotherapy</i>
<i>TUNA</i> .....	<i>Transurethral needle ablation of the prostate</i>
<i>TURP</i> .....	<i>Transurethral resection of the prostate</i>
<i>TUVP</i> .....	<i>Transurethral vaporization of the prostate</i>
<i>TV or Vt</i> .....	<i>Tidal volume</i>
<i>TVP</i> .....	<i>Transurethral electrovaporization of the prostate</i>
<i>Va</i> .....	<i>Alveolar gas volume</i>
<i>VC</i> .....	<i>Vital capacity</i>
<i>VIP</i> .....	<i>Vasoactive intestinal peptide</i>
<i>Vl</i> .....	<i>Actual volume of the lung</i>

## INTRODUCTION

**C**hronic obstructive pulmonary disease (COPD), predominantly prevalent in men, is a chronic inflammatory disorder of the airway and lungs. COPD is one of the most prevalent diseases and the third leading cause of death globally (*World Health Organization, 2006*). Patients with COPD usually present with progressive dyspnoea, shortness of breath and productive cough. Moreover, they frequently experience various comorbid conditions, such as cardiovascular disease, metabolic disorder, dementia and skeletal muscle dysfunction (*Negewo et al., 2015; Liao et al., 2015*). These comorbidities might have a significant effect on patient outcome (*Smith et al., 2014*). COPD is currently recognised as a chronic systemic inflammatory state because the inflammation involves the lung and may contribute to various extrapulmonary effects (*Agusti et al., 2008; Fabbri et al., 2007*).

Benign prostatic hyperplasia (BPH) is a common medical condition in older male populations. Approximately 14% of men aged 40–49 years are estimated to have BPH, and the prevalence increases to >50% in men aged 60 years and over (*Garraway et al., 1991; Thorpe, 2003*). Patients with BPH usually present with lower urinary tract symptoms (LUTS), such as urinary urgency and retention, considerably affecting the quality of their lives. In addition to ageing, other reported predisposing factors for BPH are metabolic syndrome, obesity

and reduced physical activity (*De Nunzio et al., 2012; Parsons et al., 2013; Sea et al., 2009*).

Although COPD and BPH are associated with chronic inflammation of the airway and prostate, respectively (*Shaw et al., 2014; Bostanci et al., 2013*) and are common disorders in ageing male populations, the relationship between these two conditions has rarely been explored. In addition, previous studies have suggested that COPD and BPH might share an underlying pathophysiology. For example, higher levels of interleukin (IL-6) and C reactive protein (CRP) in serum or sputum were observed in both patients with COPD and BPH. (*Grubek-Jaworska et al., 2012; Karadag et al., 2008; Schenk et al., 2010*) Moreover, while patients with COPD appear to be more physically inactive than their counterpart without COPD (*Spruit et al., 2015*) studies have suggested that level of physical activity was negatively associated with BPH risk. This implies that physical inactivity among patients with COPD might also be a contributing factor for BPH development (*Parsons et al., 2008*).

Lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) comprises of storage symptoms (frequency, urgency, nocturia, and urinary incontinence) and voiding symptoms (weak stream, intermittency, hesitancy, straining and terminal dribbling) (*Fitzpatrick et al., 2006; Abrams et al., 2002*). The storage sub-classification category of LUTS is same as the overactive

bladder syndrome (OAB), which has been previously defined by the International Continence Society (ICS) as ‘urgency, with or without urge incontinence, usually with frequency and nocturia (*Abrams et al., 2002*).

## **AIM OF THE WORK**

**T**he aim of study was to Assess the effect of medical treatment of symptomatic prostatic hyperplasia in pulmonary fuction tests of patients with chronic obstructive pulmonary disease, and spirometric variables before and after treatment.